These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

667 related items for PubMed ID: 18302519

  • 1. The prevalence of transient thyrotoxicosis after antithyroid drug therapy in patients with Graves' disease.
    Kubota S, Takata K, Arishima T, Ohye H, Nishihara E, Kudo T, Ito M, Fukata S, Amino N, Miyauchi A.
    Thyroid; 2008 Jan; 18(1):63-6. PubMed ID: 18302519
    [Abstract] [Full Text] [Related]

  • 2. Transient hyperthyroidism after withdrawal of antithyroid drugs in patients with Graves' disease.
    Kubota S, Tamai H, Ohye H, Fukata S, Kuma K, Miyauchi A.
    Endocr J; 2004 Apr; 51(2):213-7. PubMed ID: 15118273
    [Abstract] [Full Text] [Related]

  • 3. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK, Yoo WS, Kim DW, Chung HK.
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [Abstract] [Full Text] [Related]

  • 4. Predicting a relapse of Graves' hyperthyroidism in adults during the early phase of treatment with anti-thyroid drugs.
    Jonas M, Ambroziak U, Bednarczuk T, Nauman J.
    Endokrynol Pol; 2006 Sep; 57(6):596-604. PubMed ID: 17253432
    [Abstract] [Full Text] [Related]

  • 5. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A.
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
    Izumi Y, Takeoka K, Amino N.
    Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
    [Abstract] [Full Text] [Related]

  • 8. Serial changes in liver function tests in patients with thyrotoxicosis induced by Graves' disease and painless thyroiditis.
    Kubota S, Amino N, Matsumoto Y, Ikeda N, Morita S, Kudo T, Ohye H, Nishihara E, Ito M, Fukata S, Miyauchi A.
    Thyroid; 2008 Mar; 18(3):283-7. PubMed ID: 18001177
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Long-term follow up after antithyroid drug treatment in Graves' disease].
    Wille T, Müller B, Noth D, Bürgi U, Diem P.
    Praxis (Bern 1994); 2006 Jul 19; 95(29-30):1121-7. PubMed ID: 16916174
    [Abstract] [Full Text] [Related]

  • 12. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D, de Nayer P, Bex M, Belgian Collaborative Study Group on Graves' Disease.
    Eur J Endocrinol; 2001 May 19; 144(5):475-83. PubMed ID: 11331213
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.
    Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A.
    Thyroid; 1997 Jun 19; 7(3):369-75. PubMed ID: 9226205
    [Abstract] [Full Text] [Related]

  • 16. Successful use of iodine and levothyroxine to treat Graves' disease in a pregnant patient with allergy to antithyroid drugs and high thyrotropin-binding inhibitor immunoglobulin after radioiodine therapy.
    Kubota S, Ohye H, Sasaki I, Nishihara E, Kudo T, Fukata S, Amino N, Kuma K, Mitsuda N, Miyauchi A.
    Thyroid; 2005 Dec 19; 15(12):1373-6. PubMed ID: 16405411
    [Abstract] [Full Text] [Related]

  • 17. TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs.
    Okamoto Y, Tanigawa S, Ishikawa K, Hamada N.
    Endocr J; 2006 Aug 19; 53(4):467-72. PubMed ID: 16820704
    [Abstract] [Full Text] [Related]

  • 18. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study.
    Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, Beninati S, Messina M.
    J Endocrinol Invest; 2008 Oct 19; 31(10):866-72. PubMed ID: 19092290
    [Abstract] [Full Text] [Related]

  • 19. Two Graves' disease patients who spontaneously developed hypothyroidism after antithyroid drug treatment: characteristics of epitopes for thyrotropin receptor antibodies.
    Chung HK, Kim WB, Park DJ, Kohn LD, Tahara K, Cho BY.
    Thyroid; 1999 Apr 19; 9(4):393-9. PubMed ID: 10319947
    [Abstract] [Full Text] [Related]

  • 20. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease.
    Zimmermann-Belsing T, Nygaard B, Rasmussen AK, Feldt-Rasmussen U.
    Eur J Endocrinol; 2002 Feb 19; 146(2):173-7. PubMed ID: 11834425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.